专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5840721A Imidazole derivatives as MDR modulators 失效
标题翻译：咪唑衍生物作为MDR调节剂
公开(公告)号：US5840721A
公开(公告)日：1998-11-24
申请号：US951695
申请日：1997-10-16
申请人： Adnan M. M. Mjalli , Chengzhi Zhang
发明人： Adnan M. M. Mjalli , Chengzhi Zhang
IPC分类号： C07D233/64 , A61K31/4164 , A61K31/423 , A61K31/428 , A61K31/454 , A61K31/496 , A61K31/5377 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/56 , C07D233/61 , C07D413/10 , C07D417/10 , C07D521/00 , A61K31/415 , C07D233/02 , C07D233/04
CPC分类号： C07D233/64 , A61K31/4164 , A61K31/4178 , A61K31/42 , A61K31/423 , A61K31/428 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D413/10 , C07D417/10
摘要： The present invention relates to polysubsituted imidazole having formula 1 ##STR1## These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
摘要翻译：本发明涉及具有式1的多取代的咪唑。式1这些化合物可用于恢复多药耐药细胞对癌症化学治疗剂的敏感性。

2. 发明授权

US5723451A Nitric oxide synthase (NOS) inhibitors 失效
标题翻译：一氧化氮合成酶（NOS）抑制剂
公开(公告)号：US5723451A
公开(公告)日：1998-03-03
申请号：US694998
申请日：1996-08-09
申请人： Adnan M. M. Mjalli , Sepehar Sarshar , Chengzhi Zhang
发明人： Adnan M. M. Mjalli , Sepehar Sarshar , Chengzhi Zhang
IPC分类号： A61K31/495 , A61K31/496
CPC分类号： A61K31/495 , A61K31/496
摘要： There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the Formula I: ##STR1## to a patient in need of such inhibition such as hypotension, inflammation, autoimmune diseases and septic shock and the like.
摘要翻译：公开了通过给予需要这种抑制的患者例如低血压，炎症，自身免疫性疾病和败血性休克等的式I化合物：IMA图像抑制诱导型一氧化氮合酶的方法。

3. 发明授权

US5866569A Naphthalenedione nitric oxide synthase (NOS) inhibitors 失效
公开(公告)号：US5866569A
公开(公告)日：1999-02-02
申请号：US928183
申请日：1997-09-12
申请人： Adnan M. M. Mjalli , Sepehar Sarshar , Chengzhi Zhang
发明人： Adnan M. M. Mjalli , Sepehar Sarshar , Chengzhi Zhang
IPC分类号： A61K31/495 , A61K31/496 , A61K31/535 , A61K31/12 , A61K31/415
CPC分类号： A61K31/495 , A61K31/496
摘要： There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the formula I:. when R.sub.2 is H then R.sub.1 is selected from the group consisting of:1) aryl,--NH--C.sub.0 -C.sub.10 alkyl -aryl, N-(C.sub.0 -C.sub.10 alkyl substituted aryl).sub.2, --C.sub.0 -C.sub.10 alkyl substituted aryl, --N(C.sub.0 -C.sub.10 alkyl substituted aryl)(C.sub.0 -C.sub.10 alkyl), wherein "Aryl" is optionally attached to Compound I through C or N and is selected from the group consisting of isoindanolyl, isoindolinyl, tetrahydroquinolyl, phenyl, naphthyl, pyridyl, furyl, pyrryl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, triazolyl, tetrazolyl, pyrazinyl,pyrimidyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl, and benzoxazolyl; and the term "substituted aryl" denotes mono-, di- and/or tri-substituted aryl wherein aryl is as defined above and in which the substituents are independently selected from the group consistng of H, trifluoromethyl, amino, hydroxy, halo, nitro, --O--C.sub.1 -C.sub.6 alkyl, --S--C.sub.1 -C.sub.6 alkyl, --NH--C.sub.1 -C.sub.6 alkyl, --N (C.sub.1 -C.sub.6 allyl).sub.2, --C(O) --C.sub.1 -C.sub.6 alkyl, --NHC(O) C.sub.1 -C.sub.6 alkyl, --C.sub.1 -C.sub.11 COO.sub.2 R wherein R.dbd.C.sub.1 -C.sub.11 alkyl, or --C.sub.1 -C.sub.11 alkylphenyl, --C.sub.1 -C.sub.11 CONHR wherein R.dbd.C.sub.1 -C.sub.11 alkyl or C.sub.1 -C.sub.11 alkylphenyl, carboxy, --C(O) O C.sub.1 -C.sub.6 alkyl; trans-CH.dbd.CHCO.sub.2 R; wherein R.dbd.C.sub.1 -C.sub.11 alkyl or C.sub.1 -C.sub.6 alkylphenyl, trans CH.dbd.CHCONHR; wherein R.dbd.C.sub.1 -C.sub.11 alkyl or C.sub.1 -C.sub.11 alkylphenyl;2) cyclic --N(CH.sub.2 CH.sub.2).sub.2 Y, cyclic NCHA(CH.sub.2).sub.3, or --NH C.sub.2 -C.sub.11 alkyl-Y wherein A=i) C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkylaryl or,ii) COZR.sub.3 wherein Z=oxygen, NH and R.sub.3 =H, or C.sub.1 -C.sub.10 alkyl, or C.sub.0 -C.sub.10 alkylaryl wherein aryl group is as defined in (1) above, and Y=i) oxygen,or S, or NH orii) NC.sub.0 -C.sub.10 alkyl oriii) NC.sub.1 -C.sub.10 alkylsubstituted aryl,iv) NC=ZMR.sub.3 or COZR.sub.3 wherein Z=oxygen, or NH; M=C, oxygen, N, and R.sub.3 is C.sub.0 -C.sub.10 alkyl substituted aryl; wherein Z is as defined in (2iv) above and R.sub.3 is C.sub.0 -C.sub.10 alkylsubstituted aryl wherein "substituted aryl" is as defined above.; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together forming another aryl group; and X is hydrogen, halo, alkyl, alkoxy, hydroxy, nitro, amino, trifluoromethyl and aryl, to a patient in need of such inhibition such as hypotension, inflammtion, autoimmune diseases, and septic shock and the like.

4. 发明授权

US09260424B2 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase 有权
标题翻译：可溶性鸟苷酸环化酶的4,6-二氨基嘧啶刺激剂
公开(公告)号：US09260424B2
公开(公告)日：2016-02-16
申请号：US12911268
申请日：2010-10-25
申请人： Tadimeti Rao , Chengzhi Zhang
发明人： Tadimeti Rao , Chengzhi Zhang
IPC分类号： A61K31/506 , C07D403/14 , A61P11/00 , A61P19/10 , A61P9/10 , A61P9/12 , A61P25/06 , A61P13/12 , A61P3/10 , C07D471/04 , A61K31/437 , A61K45/06
CPC分类号： C07D471/04 , A61K31/437 , A61K31/506 , A61K45/06 , C07B59/002 , C07B2200/05 , A61K2300/00
摘要： The present invention relates to new 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase, pharmaceutical compositions thereof, and methods of use thereof
摘要翻译：本发明涉及可溶性鸟苷酸环化酶的新的4,6-二氨基嘧啶刺激剂及其药物组合物及其使用方法

5. 发明申请

US20150361120A1 MACROLIDE INHIBITORS OF mTOR 审中-公开
标题翻译： mTOR的MACROLIDE抑制剂
公开(公告)号：US20150361120A1
公开(公告)日：2015-12-17
申请号：US14366152
申请日：2011-03-30
申请人： Chengzhi Zhang
发明人： Chengzhi Zhang
IPC分类号： C07F9/6561 , C07D498/18
CPC分类号： C07F9/6561 , A61K31/33 , A61K31/553 , A61K45/06 , C07D498/18 , A61K2300/00
摘要： The present invention relates to new macrolide inhibitors of mTOR, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译：本发明涉及mTOR的新的大环内酯抑制剂，其药物组合物及其使用方法。

6. 发明授权

US09018232B2 Substituted N-aryl pyridinones 有权
标题翻译：取代的N-芳基吡啶酮
公开(公告)号：US09018232B2
公开(公告)日：2015-04-28
申请号：US14003106
申请日：2012-03-06
申请人： Chengzhi Zhang
发明人： Chengzhi Zhang
IPC分类号： A61K31/445 , A61K31/4418 , C07D213/64 , A61K31/4412
CPC分类号： A61K31/4412 , A61K31/4418 , C07D213/64 , Y02A50/409 , Y02A50/411
摘要： Disclosed herein are methods of administering deuterated pirfenidone and kits thereof.
摘要翻译：本文公开了施用氘代吡非尼酮及其试剂盒的方法。

7. 发明申请

US20130324569A1 PEGYLATED CYCLOPAMINE ANALOGUE, PREPARATION METHOD AND USES THEREOF 有权
标题翻译：聚乙二醇化合物类似物，其制备方法及其用途
公开(公告)号：US20130324569A1
公开(公告)日：2013-12-05
申请号：US13882797
申请日：2011-02-25
申请人： Chun Song , Chengzhi Zhang , Xin Zhao , Zhao Hu , Xiuling Xu , Youzhong Zhang , Mingyi Wang , Zhijun Sun
发明人： Chun Song , Chengzhi Zhang , Xin Zhao , Zhao Hu , Xiuling Xu , Youzhong Zhang , Mingyi Wang , Zhijun Sun
IPC分类号： A61K47/48
CPC分类号： A61K47/48215 , A61K31/133 , A61K47/60 , C08G65/33396 , C08G2650/30 , C08L2203/02
摘要： A PEGylated cyclopamine analog, preparation method, uses thereof and methods for treating proliferative diseases using the same are disclosed. The PEGylated cyclopamine analog is a compound represented by the following formula I, a compound comprising at least one group represented by the following formula I (in formula I, R is straight or branched polyethylene glycol having a molecular weight between 200 and 200,000 Dalton, L and X are linking groups), or their single enantiomers, mixture of enantiomers, mixture of diastereomers, pharmaceutically acceptable salts, solvates, or hydrates.
摘要翻译：公开了聚乙二醇化的环巴胺类似物，其制备方法，其用途和使用其的治疗增殖性疾病的方法。聚乙二醇化环胺类似物是由下式I表示的化合物，包含至少一个由下式I表示的基团的化合物（在式I中，R是分子量为200至200,000道尔顿的直链或支链聚乙二醇，L 和X是连接基团）或其单一对映异构体，对映异构体的混合物，非对映异构体的混合物，药学上可接受的盐，溶剂合物或水合物。

8. 发明授权

US08586760B2 Aminothiazole modulators of beta-3-adrenoreceptor 有权
公开(公告)号：US08586760B2
公开(公告)日：2013-11-19
申请号：US12796781
申请日：2010-06-09
申请人： Tadimeti Rao , Chengzhi Zhang
发明人： Tadimeti Rao , Chengzhi Zhang
IPC分类号： C07D277/20 , A61K31/425
CPC分类号： C07D277/40 , A61K31/426 , A61K45/06 , C07D277/22
摘要： The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.

9. 发明授权

US08575348B2 Quinolone inhibitors of lipoprotein-associated phospholipase A2 有权
标题翻译：喹诺酮抑制剂与脂蛋白相关的磷脂酶A2
公开(公告)号：US08575348B2
公开(公告)日：2013-11-05
申请号：US12845384
申请日：2010-07-28
申请人： Tadimeti Rao , Chengzhi Zhang
发明人： Tadimeti Rao , Chengzhi Zhang
IPC分类号： C07D215/38
CPC分类号： C07D401/12 , A61K31/4709
摘要： The present invention relates to new quinolone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译：本发明涉及脂蛋白相关磷脂酶A2活性的新喹诺酮抑制剂及其药物组合物及其使用方法。

10. 发明授权

US08299084B2 Piperidine inhibitors of Janus kinase 3 有权
标题翻译： Janus激酶3的哌啶抑制剂
公开(公告)号：US08299084B2
公开(公告)日：2012-10-30
申请号：US12763858
申请日：2010-04-20
申请人： Tadimeti Rao , Chengzhi Zhang
发明人： Tadimeti Rao , Chengzhi Zhang
IPC分类号： A01N43/90 , A61K31/519 , C07D487/00
CPC分类号： C07D487/04 , A61K31/519 , C07B2200/05 , Y02P20/55
摘要： The present invention relates to new piperidine inhibitors of Janus kinase 3 activity, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译：本发明涉及Janus激酶3活性的新的哌啶抑制剂及其药物组合物及其使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式